Abstract

The preparation Mutaflor contains a defined strain of physiological E. coli bacteria. One hundred and sixty-seven physicians documented the treatment of 1,074 patients suffering from functional or chronic inflammatory bowel disease. For all indications the tolerance of Mutaflor was judged to be good to very good in over 90% of the cases. Adverse reactions which needed treatment or led to termination of the therapy, were reported in 1.5% of the cases. Initially occurring side effects, which did not need treatment and disappeared spontaneously, were observed in 2.8% of the cases. Interactions with additional or concomitant drugs did not occur. As a parameter for the evaluation of efficacy, the subjective assessment of the results by physicians and patients was used. In 84% of the patients with functional intestinal disorders and 78% of the patients with chronic inflammatory bowel disease results of treatment were judged to be good to very good.